...
首页> 外文期刊>Medicine. >Efficacy and safety of Yukgunja-Tang for treating anorexia in patients with cancer: The protocol for a pilot, randomized, controlled trial
【24h】

Efficacy and safety of Yukgunja-Tang for treating anorexia in patients with cancer: The protocol for a pilot, randomized, controlled trial

机译:Yukgunja-Tang治疗癌症患者厌食的疗效和安全性:试点,随机,对照试验的议定书

获取原文

摘要

Background: Anorexia is a common cause of malnutrition and is associated with negative effects on the quality of life (QOL) for patients with cancer . Management of appetite is the key to improving both the QOL and the prognosis for such patients. Yukgunja-tang (YGJT) is a traditional herbal medicine extensively prescribed in Korea as a remedy for various gastrointestinal syndromes. Currently, no standardized herbal medicine treatment exists for patients with cancer who are suffering from anorexia after surgery, chemotherapy, and/or radiotherapy. For that reason, this study aims to examine the efficacy and the safety of using YGJT to treat anorexia in such patients and to establish whether or not YGJT can be recommended as the primary therapy. Methods: We will enroll 52 cancer patients diagnosed with anorexia . The enrolled participants will be randomly allocated to 2 groups: The control group will receive nutrition counseling, and the YGJT group will receive nutrition counseling and be administered YGJT at a dose of 3 g twice a day for 4 weeks (a total of 56 doses of 3.0 g per dose). The primary outcome of this study is the change in the score on the anorexia /cachexia subscale (A/CS) of the Functional Assessment of Anorexia /Cachexia Therapy (FAACT). The secondary outcomes are the changes in the FAACT score with the A/CS score excluded, the score on the Visual Analogue Scale (VAS) for appetite, the weight and the body mass index (BMI), and laboratory tests for compounds such as leptin, tumor necrosis factor-α (TNF-α), ghrelin, and IL-6. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (CBC, chemistry, urine test), and adverse events, will be documented on the case report form (CRF) at every visit. Conclusion: This study is the first randomized controlled trial to investigate the efficacy and the safety of using YGJT for treating patients with cancer -related anorexia in Korea. We designed this study based on previous research about YGJT. This study will serve as a pilot and provide data for planning further clinical trials on herbal medicine and cancer -related anorexia . Trial registration: Clinical Research Information Service (CRIS), Republic of Korea, ID: KCT0002847. Registered retrospectively on 3 April 2018.
机译:背景:厌食症是营养不良的常见原因,与癌症患者的寿命质量(QOL)的负面影响有关。食欲管理是改善QoL和该等患者预后的关键。 Yukgunja-Tang(YGJT)是一种传统的草药,其在韩国广泛规定的各种胃肠综合征的补救措施。目前,患有手术,化疗和/或放疗后患有厌食的患者的患者没有标准化的草药治疗。因此,本研究旨在审查使用YGJT治疗这些患者的患者的疗效和安全性,并建立ygjt是否可以作为主要疗法。方法:我们将纳入患有厌食症的52名癌症患者。登记的参与者将随机分配给2组:控制组将获得营养咨询,ygjt组将获得营养咨询,并在每天每天两次以3克的剂量给予ygjt持续4周(共56剂每剂量3.0克)。本研究的主要结果是厌食/恶病症治疗功能评估(FAACT)功能评估的厌食/恶作剧次级血统(A / CS)的分数的变化。二次结果是FAAC分数与A / CS得分的变化排除,食欲,重量和体重指数(BMI)的可视模拟量表(VAS)的得分,以及瘦素等化合物的实验室测试,肿瘤坏死因子-α(TNF-α),Ghrelin和IL-6。所有与安全评估有关的变量,如生命体征,心电图结果,实验室测试结果(CBC,化学,尿检)和不良事件,将在每次访问时记录案件报告表格(CRF)。结论:本研究是第一个随机对照试验,用于研究使用YGJT治疗韩国癌症患者的疗效和安全性。我们根据以前的ygjt研究设计了这项研究。本研究将作为试点,并提供规划在草药和癌症厌食症的进一步临床试验的数据。审判登记:临床研究信息服务(CRIS),大韩民国,ID:KCT0002847。 2018年4月3日回顾性地注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号